Towards Healthcare
Cell & Gene Therapy (CGT) Biomanufacturing Market to Reach USD 41.41 Bn by 2034

Cell & Gene Therapy (CGT) Biomanufacturing Market

Projections indicate that, the global cell & gene therapy (CGT) biomanufacturing market will increase from USD 14.03 billion in 2024 to USD 41.41 billion by 2034, experiencing a CAGR of 11.43% over the next 10 years. Increasing outsourcing & contract manufacturing have driven the growth of the market. North America led the global market owing to the advanced healthcare infrastructure in the region.

  • Insight Code: 6092
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

The cell & gene therapy (CGT) biomanufacturing market in 2025 is valued at USD 14.03 billion and is projected to climb to USD 41.41 billion by 2034, with a CAGR of 11.43% over the forecast period.

North America is leading the cell & gene therapy (CGT) biomanufacturing market due to the growing clinical application, supportive regulatory properties, and presence of advanced infrastructure.

Some key players include Lonza, Thermo Fisher Scientific, Catalent Inc., Fujifilm Diosynth Biotechnologies, WuXi Advanced Therapies / WuXi AppTec, Samsung Biologics, and AGC Biologics, among others.

Biotechnology Innovation Organization (BIO), Personalized Medicine Coalition, ASGCT - American Society of Gene & Cell Therapy, Government of Canada, Alliance for Regenerative Medicine, Food and Drug Administration, clinicaltrials.gov, GOV.UK